CN105982336A - 一种肿瘤康复型水产胶原蛋白肽食品 - Google Patents
一种肿瘤康复型水产胶原蛋白肽食品 Download PDFInfo
- Publication number
- CN105982336A CN105982336A CN201610314066.7A CN201610314066A CN105982336A CN 105982336 A CN105982336 A CN 105982336A CN 201610314066 A CN201610314066 A CN 201610314066A CN 105982336 A CN105982336 A CN 105982336A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- collagen
- solution
- lys
- magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 142
- 108010035532 Collagen Proteins 0.000 title claims abstract description 142
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 97
- 229920001436 collagen Polymers 0.000 title claims abstract description 84
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 43
- 235000013305 food Nutrition 0.000 title claims abstract description 38
- 238000011084 recovery Methods 0.000 title abstract 4
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 10
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 114
- 239000004005 microsphere Substances 0.000 claims description 82
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 62
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims description 62
- 239000006260 foam Substances 0.000 claims description 53
- 239000007788 liquid Substances 0.000 claims description 38
- 239000012528 membrane Substances 0.000 claims description 35
- 238000000926 separation method Methods 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241000251468 Actinopterygii Species 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 25
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 23
- 239000004833 fish glue Substances 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- 239000011669 selenium Substances 0.000 claims description 16
- 229910052711 selenium Inorganic materials 0.000 claims description 16
- 235000011649 selenium Nutrition 0.000 claims description 16
- 239000011573 trace mineral Substances 0.000 claims description 16
- 235000013619 trace mineral Nutrition 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 230000003213 activating effect Effects 0.000 claims description 15
- 238000007664 blowing Methods 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 15
- 238000005374 membrane filtration Methods 0.000 claims description 15
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 238000010257 thawing Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 239000003925 fat Substances 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 12
- 229910001385 heavy metal Inorganic materials 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
- 108090000145 Bacillolysin Proteins 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 108090000942 Lactalbumin Proteins 0.000 claims description 10
- 102000004407 Lactalbumin Human genes 0.000 claims description 10
- 102000035092 Neutral proteases Human genes 0.000 claims description 10
- 108091005507 Neutral proteases Proteins 0.000 claims description 10
- 230000008901 benefit Effects 0.000 claims description 10
- 239000003292 glue Substances 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000787 lecithin Substances 0.000 claims description 10
- 229940067606 lecithin Drugs 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000010025 steaming Methods 0.000 claims description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims description 9
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 9
- 235000019163 vitamin B12 Nutrition 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000013522 chelant Substances 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 7
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 7
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229960001231 choline Drugs 0.000 claims description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 7
- 229910052804 chromium Inorganic materials 0.000 claims description 7
- 239000011651 chromium Substances 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229910052748 manganese Inorganic materials 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- 229910052750 molybdenum Inorganic materials 0.000 claims description 7
- 239000011733 molybdenum Substances 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 229940055726 pantothenic acid Drugs 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 7
- 239000011713 pantothenic acid Substances 0.000 claims description 7
- 239000011574 phosphorus Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 235000019175 phylloquinone Nutrition 0.000 claims description 7
- 239000011772 phylloquinone Substances 0.000 claims description 7
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 7
- 229960001898 phytomenadione Drugs 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- 235000005282 vitamin D3 Nutrition 0.000 claims description 7
- 239000011647 vitamin D3 Substances 0.000 claims description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- 229940021056 vitamin d3 Drugs 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 239000006247 magnetic powder Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000005187 foaming Methods 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 235000014593 oils and fats Nutrition 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 10
- 238000001959 radiotherapy Methods 0.000 abstract description 10
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 230000022131 cell cycle Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 4
- 208000019505 Deglutition disease Diseases 0.000 abstract description 3
- 206010047700 Vomiting Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- 241000251730 Chondrichthyes Species 0.000 abstract 1
- 108010046377 Whey Proteins Proteins 0.000 abstract 1
- 102000007544 Whey Proteins Human genes 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000001055 chewing effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 235000021119 whey protein Nutrition 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 244000234623 Coprinus comatus Species 0.000 description 2
- 235000004439 Coprinus comatus Nutrition 0.000 description 2
- 241001149422 Ganoderma applanatum Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108010001062 polysaccharide-K Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及医用食品领域,公开了一种肿瘤康复型水产胶原蛋白肽食品,每100g中包含:金枪鱼皮胶原蛋白肽粉12.4‑14.4g,鲨鱼皮胶原蛋白肽粉7‑8g,乳清蛋白粉3.5‑4.5g,MCT脂肪10‑12g,LCT脂肪9‑11g,碳水化合物41‑42g,灵芝多糖2.4‑2.6g,姬松茸多糖2.4‑2.6g,以及其他维生素和微量元素等多种营养成分。本发明适用于肿瘤放、化疗患者。能干预细胞***周期,有利于诱导肿瘤细胞凋亡;能减轻脏器负担、增强机体免疫力。适用于营养不良的肿瘤患者,包括恶病质、厌食症、咀嚼及吞咽障碍等患者。能有效减轻放、化疗过程中出现的副反应,有效减缓呕吐症状,降低肿瘤转移。
Description
技术领域
本发明涉及医用食品领域,尤其涉及一种肿瘤康复型水产胶原蛋白肽食品。
背景技术
肿瘤癌症的高增长率和高死亡率,给个人、家庭和社会带来了沉重压力,给病人带来了巨大的痛苦,如何有效***疾病和改善肿瘤患者的生活质量也成为世界性难题。
肿瘤患者在治疗期间,会出现摄食量减少,蛋白质代谢异常,血浆蛋白质水平降低等情况,因此,需要肿瘤患者服用专门针对肿瘤康复的肿瘤康复医用食品。医用食品不同于药品、普通食品、保健食品以及膳食补充剂。食品法典委员会(CAC) 对医用食品进行了定义:即需要特殊膳食管理的病人在医生的指导下进行服用的一类具有特殊膳食用途的食品,属于特殊膳食的一类。美国FDA对医用食品提出三个必备要素:满足特殊的营养需要;在营养医师的指导下服用;适用于需要特殊膳食管理的人群。我国尚未对医用食品定义。
现有的针对肿瘤康复食品品类繁多,例如申请号为200610036675.7的中国专利公开了一种抗肿瘤保健食品的产品配方,采用乌梢蛇原粉为主要原料,配以各种辅料营养增强剂,研制而成的一种抗肿瘤保健食品。具体配方为乌梢蛇原粉、辅酶Q10,白蛋白多肽,谷胱甘肽,金属硫蛋白,维生素B12,维生素E,维生素C,硒蛋白,灵芝孢子破壁粉。例如申请号为201410723980.8的中国专利公开了具有抗肿瘤功效的保健食品及其制备工艺,它由灰树花多糖、云芝多糖、香菇多糖、树舌多糖、鸡腿菇多糖组成,其重量百分比为:灰树花多糖10-65%、云芝多糖10-50%、香菇多糖5-40%、树舌多糖 10-30%、鸡腿菇多糖5-10%,通过培养、过滤、提纯、干燥、粉碎、复配、灌装制得。
上述保健食品营养较为全面,能够增强人体的免疫力,但是上述食品均为保健食品,无法作为医用食品使用;上述保健食品营养配比还不够合理,无需医嘱,只是盲目地进行营养摄入,却并不能使肿瘤患者增强对肿瘤的预防和抑制作用,因此无法有效地辅助肿瘤患者进行康复。因此,目前市场上缺少肿瘤康复型的医用食品。
发明内容
为了解决上述技术问题,本发明提供了一种肿瘤康复型水产胶原蛋白肽食品。本发明的肿瘤康复型水产胶原蛋白肽食品属于医用食品,为高蛋白质、高能量密度、低碳水化合物肠内全营养配方。适用于肿瘤放、化疗患者。能干预细胞***周期,有利于诱导肿瘤细胞凋亡;能减轻脏器负担、增强机体免疫力。适用于营养不良的肿瘤患者,包括恶病质、厌食症、咀嚼及吞咽障碍等患者。能有效减轻放、化疗过程中出现的副反应,有效减缓呕吐症状,降低肿瘤转移。
本发明的具体技术方案为:一种肿瘤康复型水产胶原蛋白肽食品,每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉12.4-14.4g,鲨鱼皮胶原蛋白肽粉7-8g,乳清蛋白粉3.5-4.5g,MCT脂肪10-12g,LCT脂肪9-11g,碳水化合物41-42g,灵芝多糖2.4-2.6g,姬松茸多糖2.4-2.6g,烟酸4-4.1mg,叶酸41-43μg,生物素39-41μg,胆碱78.6-79mg,泛酸13-15mg,牛磺酸52-53mg, L-肉碱52-53mg,卵磷脂98-102mg,谷氨酰胺98-102mg,核苷酸9-11mg,精氨酸66-68mg,DHA 49-51mg,维生素A 1400-1600IU,维生素D3 98-102IU,维生素E 21.1-21.5IU,维生素C 38-42mg,维生素B1 0.4-0.6mg,维生素B2 0.5-0.7mg,维生素B6 0.7-0.8mg,维生素K1 22.7-22.9μg,维生素B12 0.7-0.9μg,以及含有微量元素的多种无机盐。
其中所有所述无机盐中微量元素的含量如下:钙148-152mg,磷134-136mg,镁80-82mg,锌3.7-3.9mg,铁3.0-3.2mg,铜0.40-0.42mg,锰0.77-0.79mg,钠116.6-117.0mg,钾187.0-187.4mg,氯172.6-173.0mg,碘16.02-16.04μg,铬15.2-15.4μg,钼22.5-23.0μg,硒12-14μg。
本发明的品为高蛋白质、高能量密度、低碳水化合物肠内全营养配方。适用于创伤、应激或肿瘤放、化疗患者。能修复受损细胞膜,干预细胞***周期,有利于诱导肿瘤细胞凋亡;能提高机体抗氧化能力,减轻脏器负担、加速伤口愈合,增强机体免疫力。
本品中以金枪鱼皮胶原蛋白肽粉、鲨鱼皮胶原蛋白肽粉和乳清蛋白粉为主要原料,高含量的海洋性胶原蛋白多聚肽有抑制肿瘤转移的作用。由乳清蛋白、胶原蛋白肽及游离氨基酸组成的氮源产生互补作用,提高生物利用度。胶原蛋白肽中含有丰富的甘氨酸和丙氨酸,有助于缓解肌肉蛋白的高分解代谢,提高谷氨酰胺活性。配方中的精氨酸、谷氨酰胺和核苷酸等具有免疫增强作用,有利于创伤愈合、降低感染的作用。 维生素A、C、E的协同比例能提高抗氧化活性,有利于防止放、化疗造成的氧化损伤。适量维生素D、K、B6、B12和叶酸对抗肿瘤有辅助治疗作用。采用LCT/MCT为能量物质,添加姬松茸多糖、卵磷脂等活性成分,能有效缓解肿瘤治疗的毒副作用。
作为优选,每100g肿瘤康复型水产胶原蛋白肽食品中包含以下物质:
金枪鱼皮胶原蛋白肽粉13.4g,鲨鱼皮胶原蛋白肽粉7.5g,乳清蛋白粉4g,MCT脂肪11g,LCT脂肪10g,碳水化合物41.6g,灵芝多糖2.5g,姬松茸多糖2.5g,烟酸4.05g,叶酸42μg,生物素40μg,胆碱78.8mg,泛酸14mg,牛磺酸52.5mg, L-肉碱52.5mg,卵磷脂100mg,谷氨酰胺100mg,核苷酸10mg,精氨酸67mg,DHA 50mg,维生素A 1500IU,维生素D3 100IU,维生素E 21.3IU,维生素C 40mg,维生素B1 0.5mg,维生素B2 0.6mg,维生素B6 0.75mg,维生素K1 22.8μg,维生素B12 0.8μg,以及含有微量元素的多种无机盐。
其中所有所述无机盐中微量元素的含量如下:钙150mg,磷135mg,镁81mg,锌3.8mg,铁3.1mg,铜0.41mg,锰0.78mg,钠116.8mg,钾187.2mg,氯172.8mg,碘16.03μg,铬15.3μg,钼22.75μg,硒13μg。
作为优选,所述金枪鱼皮胶原蛋白肽粉中,分子量在600-1000Da区间内占比90%以上;所述鲨鱼皮胶原蛋白肽粉中,分子量在10000-12000Da以内占比90%以上。
水产动物的胶原蛋白肽在某个分子量区间内具有较好的抗肿瘤效果,但是不同水产动物的胶原蛋白肽最佳分子量区间大为不同,本申请人在经过大量实验以及创造性研究后,发现将分子量在600-1000Da区间的金枪鱼胶原蛋白与分子量在10000-12000Da鲨鱼皮胶原蛋白肽进行特定比例的复配后,能够产生协同作用,对抗肿瘤具有很好的抑制效果。
作为优选,所述碳水化合物选自聚葡糖糖、麦芽糊精、蔗糖、果糖、木糖中的至少两种。
作为优选,所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉的制备方法如下:
a、原料解冻清洗:对鱼皮进行流水解冻,解冻时间为2-5h;完全解冻后将鱼皮洗净。原料应该保持新鲜、清洁、无异味。
b、原料预处理:将鱼皮添加到5-10倍浓度为3-5wt%的氢氧化钠溶液中,在20-30℃下脱脂4-6h,然后取鱼皮用水洗净。
c、蒸煮熬胶:将鱼皮在90-100℃下进行蒸煮熬胶8-12h,取生成的鱼皮胶,并对鱼皮胶通过离心处理与油脂分离,离心速率为1000r/min。
d、酶解:将鱼皮胶添加到含有中性蛋白酶的酶解液中进行酶解;其中中性蛋白酶的浓度为0.05-0.25wt%,酶解液质量为鱼皮胶质量的2-4倍,酶解温度为30-45℃,酶解液pH至控制在6-8,酶解时间为30-60min。
e、炭脱、板框过滤:向酶解液中添加质量为酶解液1-2wt%的活性炭,并将酶解液加热到70-80℃,脱色30-50min;将脱色后的酶解液转移至板框过滤池内进行过滤,取澄清液。
f、分离纯化:将澄清液转移至泡沫分离柱中进行鼓气起泡,并收集泡沫液,,在鼓气的同时向泡沫分离柱中注水;鼓气速率为3-5L/min,注水速率为0.1-0.3L/min,泡沫分离柱中液体的装载高度与泡沫分离柱内径比为8-10:1,澄清液温度保持在25-35℃;待收集的泡沫液灭泡后,用离子交换器对泡沫液进行重金属分离;向重金属分离后的泡沫液中添加质量为泡沫液1-2%的磁性亲和微球并分散均匀,静置亲和吸附50-70min后利用磁场使磁性亲和微球聚集;分离出磁性亲和微球后,用pH值为7.2的Tris-HCl缓冲液对磁性亲和微球进行洗脱,再次利用磁场分离出磁性亲和微球后,得到洗脱液,将洗脱液在75-85℃下储存备用。
板框过滤后澄清液中的不溶性杂质基本分离完毕,基本只存在溶解性杂质以及重金属离子等。对澄清液进行泡沫分离纯化,由于蛋白物质具有一定的表面活性,能够在液体气泡后聚集在泡沫表面,收集泡沫液,能够将蛋白物质与其他物质进行分离。在泡沫分离过程中,由于泡沫分离柱中水分的不断变少,使得液体中蛋白物质的浓度升高,导致浓度超过临界胶束浓度, 从而容易将其他可溶性杂质附带在泡沫表面,影响分离效果,进行注水能够有效维持液体中蛋白浓度。用离子交换器能够对泡沫液中的一同附着的重金属进行分离,再用磁性亲和微球对泡沫液中的目标蛋白物质进行亲和吸附,使得胶原蛋白肽的纯度更高。
g、浓缩:将洗脱液先后输入双效浓缩锅和四效浓缩锅中进行浓缩,制得浓缩液,所述浓缩液的折光度控制在5-6,浓缩后浓缩液在50-60℃下储存。
h、膜过滤:将浓缩液通过二级0.22微米膜过滤器进行除杂除菌;其中膜过滤温度小于45℃,一级过滤压力小于0.25MPa,二级过滤压力小于0.4MPa。
i、多肽分级:采用超滤膜或纳滤膜对膜过滤后的浓缩液按分子量进行分离,得到目标分子量的胶原蛋白肽。
j、喷雾干燥:对胶原蛋白肽进行喷雾干燥,制得胶原蛋白肽粉;喷雾温度为80-90℃,喷雾干燥后水产胶原蛋白肽粉的含水率小于等于5wt%。
本发明制备的金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉,纯度高,得率高,分子量分布区间小,在目标分子量区间内的胶原蛋白肽含量高。
作为优选,在金枪鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在1000Da以上的胶原蛋白肽,再用纳滤膜截留分子量在600Da以上的胶原蛋白肽,得到分子量在600-1000Da之间的胶原蛋白肽;在鲨鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在12000Da以上的胶原蛋白肽,再用超滤膜截留分子量在1000Da以上的胶原蛋白肽,得到分子量在10000-1200Da之间的胶原蛋白肽。
作为优选,所述磁性亲和微球由以下方法制得:将海藻酸钠、聚乙二醇、壳聚糖、正庚烷、乙酸、水按质量比2-3:1:2:0.5:3-5:100混合溶解,搅拌均匀后制得混合液A;向混合液A中添加混合液A质量4-6%的四氧化三铁磁粉并分散均匀,得到混合液B;对混合液B进行超声波分散,同时向混合液B中匀速滴加混合液B质量40-60%的乳化液,得到混合液C;先后向混合液C中添加混合液C质量0.1-0.2%的98wt%的戊二醛和混合液C质量0.5-1倍的2.5-3.5wt%的氯化钙溶液,充分搅拌,静置1-2h,生成磁性微球;利用磁场对液体中磁性微球进行聚集,取出磁性微球后进行清洗、干燥;将磁性微球浸泡在水中溶胀15-25min,然后取出磁性微球并添加到活化液中在35-45℃下活化40-80min,磁性微球与活化液的固液比为0.5-1.0g/mL;活化后取出磁性微球并洗净,将磁性微球与肝素按质量比1.5-2.5:1进行混合,得到悬浮液,将悬浮液pH值调节至4-5,然后向悬浮液中添加悬浮液体积1.5-2.5倍的3wt%的1-乙基-3-二甲氨丙基-碳二亚胺,在4℃下静置12-18h。生成磁性亲和微球,最后从悬浮液中取出磁性亲和微球,洗净、干燥,备用。
本发明的磁性微球,以四氧化三铁磁粉为磁核,以海藻酸钠、聚乙二醇、壳聚糖为磁核的主要包衣材料,以正庚烷为致孔剂,添加戊二醛和氯化钙溶液后,交联成型,具有多孔性,比表面积大,吸附容量大,分散性佳,粒径均一性好。
作为优选,所述乳化液为体积占比为30-40%的司盘-80无水乙醇混合液,乳化液在10-20min内滴加完毕。
作为优选,所述活化液由1mol/L的氢氧化钠溶液、二甲基亚砜和环氧氯丙烷按体积比4-6:1:0.5-0.7组成。
作为优选,所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉在制备过程中,在多肽分级之后、喷雾干燥之前,将目标分子量的胶原蛋白肽稀释10-30倍,向稀释液中添加含钙无机盐,在35-45℃下螯合10-20min,接着向稀释液中添加含硒无机盐,在35-45℃下螯合10-20min;其中含钙无机盐、含硒无机盐的质量分别为稀释液质量的0.1-0.2%。
对胶原蛋白肽表面进行修饰,能够使其含有微量元素,与微量元素螯合后,吸收性好。
与现有技术对比,本发明的有益效果是:1、营养全面均衡:可作为唯一营养来源。 2、由胶原蛋白肽和乳清蛋白提供氮源:必需氨基酸谱完全,生物利用度高。 3、谷氨酰胺:修复放、化疗后肠粘膜损伤,避免因肠粘膜屏障受损导致的感染、腹泻等并发症。同时降低肌肉分解,改善白细胞及网状内皮***的功能。 4、精胺酸、DHA:能促进、调节免疫功能 5、姬松茸多糖、灵芝多糖(β-D-葡聚糖):有调节免疫、抗辐射、抗肿瘤、升白细胞功能,能够有效减轻放、化疗过程中出线的副反应。如白细胞减少、胃口不好、脱发等,抗肿瘤效果明显。7、MCT/LCT,L-肉碱、卵磷脂: MCT与LCT相互支持,在L-肉碱和卵磷脂的作用下迅速产能,减少MCT的生酮作用,同时保持肠系安静。
因此,本产品为高蛋白质、高能量密度、低碳水化合物肠内全营养配方。适用于肿瘤放、化疗患者。能干预细胞***周期,有利于诱导肿瘤细胞凋亡;能减轻脏器负担、增强机体免疫力。适用于营养不良的肿瘤患者,包括恶病质、厌食症、咀嚼及吞咽障碍等患者。能有效减轻放、化疗过程中出现的副反应,有效减缓呕吐症状,降低肿瘤转移。
具体实施方式
下面结合实施例对本发明作进一步的描述。
实施例1
一种肿瘤康复型水产胶原蛋白肽食品,每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉13.4g,鲨鱼皮胶原蛋白肽粉7.5g,乳清蛋白粉4g,MCT脂肪11g,LCT脂肪10g,聚葡糖糖10g,麦芽糊精11.6g,蔗糖10g,果糖10g,灵芝多糖2.5g,姬松茸多糖2.5g,烟酸4.05g,叶酸42μg,生物素40μg,胆碱78.8mg,泛酸14mg,牛磺酸52.5mg, L-肉碱52.5mg,卵磷脂100mg,谷氨酰胺100mg,核苷酸10mg,精氨酸67mg,DHA 50mg,维生素A 1500IU,维生素D3 100IU,维生素E 21.3IU,维生素C 40mg,维生素B1 0.5mg,维生素B2 0.6mg,维生素B6 0.75mg,维生素K1 22.8μg,维生素B12 0.8μg,以及含有微量元素的多种无机盐。
其中所有所述无机盐中微量元素的含量如下:钙150mg,磷135mg,镁81mg,锌3.8mg,铁3.1mg,铜0.41mg,锰0.78mg,钠116.8mg,钾187.2mg,氯172.8mg,碘16.03μg,铬15.3μg,钼22.75μg,硒13μg。
其中,所述金枪鱼皮胶原蛋白肽粉中,分子量在600-1000Da区间内占比90%以上;所述鲨鱼皮胶原蛋白肽粉中,分子量在10000-12000Da以内占比90%以上。
所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉的制备方法如下:
a、原料解冻清洗:对鱼皮进行流水解冻,解冻时间为3.5h;完全解冻后将鱼皮洗净。
b、原料预处理:将鱼皮添加到7.5倍浓度为4wt%的氢氧化钠溶液中,在25℃下脱脂5h,然后取鱼皮用水洗净。
c、蒸煮熬胶:将鱼皮在95℃下进行蒸煮熬胶10h,取生成的鱼皮胶,并对鱼皮胶通过离心处理与油脂分离,离心速率为1000r/min。
d、酶解:将鱼皮胶添加到含有中性蛋白酶的酶解液中进行酶解;其中中性蛋白酶的浓度为0.15wt%,酶解液质量为鱼皮胶质量的3倍,酶解温度为38℃,酶解液pH至控制在6-8,酶解时间为45min。
e、炭脱、板框过滤:向酶解液中添加质量为酶解液1.5wt%的活性炭,并将酶解液加热到75℃,脱色40min;将脱色后的酶解液转移至板框过滤池内进行过滤,取澄清液。
f、分离纯化:将澄清液转移至泡沫分离柱中进行鼓气起泡,并收集泡沫液,,在鼓气的同时向泡沫分离柱中注水;鼓气速率为4L/min,注水速率为0.2L/min,泡沫分离柱中液体的装载高度与泡沫分离柱内径比为9:1,澄清液温度保持在30℃;待收集的泡沫液灭泡后,用离子交换器对泡沫液进行重金属分离;向重金属分离后的泡沫液中添加质量为泡沫液1-2%的磁性亲和微球并分散均匀,静置亲和吸附50-70min后利用磁场使磁性亲和微球聚集;分离出磁性亲和微球后,用pH值为7.2的Tris-HCl缓冲液对磁性亲和微球进行洗脱,再次利用磁场分离出磁性亲和微球后,得到洗脱液,将洗脱液在80℃下储存备用。
g、浓缩:将洗脱液先后输入双效浓缩锅和四效浓缩锅中进行浓缩,制得浓缩液,所述浓缩液的折光度控制在5.5,浓缩后浓缩液在55℃下储存。
h、膜过滤:将浓缩液通过二级0.22微米膜过滤器进行除杂除菌;其中膜过滤温度小于45℃,一级过滤压力小于0.25MPa,二级过滤压力小于0.4MPa。
i、多肽分级:采用超滤膜或纳滤膜对膜过滤后的浓缩液按分子量进行分离,得到目标分子量的胶原蛋白肽。
j、喷雾干燥:对胶原蛋白肽进行喷雾干燥,制得水产胶原蛋白肽粉;喷雾温度为80-90℃,喷雾干燥后水产胶原蛋白肽粉的含水率小于等于5wt%。
在金枪鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在1000Da以上的胶原蛋白肽,再用纳滤膜截留分子量在600Da以上的胶原蛋白肽,得到分子量在600-1000Da之间的胶原蛋白肽;在鲨鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在12000Da以上的胶原蛋白肽,再用超滤膜截留分子量在1000Da以上的胶原蛋白肽,得到分子量在10000-1200Da之间的胶原蛋白肽。
所述磁性亲和微球由以下方法制得:将海藻酸钠、聚乙二醇、壳聚糖、正庚烷、乙酸、水按质量比2.5:1:2:0.5:4:100混合溶解,搅拌均匀后制得混合液A;向混合液A中添加混合液A质量5%的四氧化三铁磁粉并分散均匀,得到混合液B;对混合液B进行超声波分散,同时向混合液B中匀速滴加混合液B质量50%的乳化液,乳化液在15min内滴加完毕,得到混合液C;先后向混合液C中添加混合液C质量0.15%的98wt%的戊二醛和混合液C质量0.75倍的3wt%的氯化钙溶液,充分搅拌,静置1.5h,生成磁性微球;利用磁场对液体中磁性微球进行聚集,取出磁性微球后进行清洗、干燥;将磁性微球浸泡在水中溶胀20min,然后取出磁性微球并添加到活化液中在40℃下活化60min,磁性微球与活化液的固液比为0.75g/mL;活化后取出磁性微球并洗净,将磁性微球与肝素按质量比2:1进行混合,得到悬浮液,将悬浮液pH值调节至4-5,然后向悬浮液中添加悬浮液体积2倍的3wt%的1-乙基-3-二甲氨丙基-碳二亚胺,在4℃下静置15h。生成磁性亲和微球,最后从悬浮液中取出磁性亲和微球,洗净、干燥,备用。
其中,所述乳化液为体积占比为35%的司盘-80无水乙醇混合液。所述活化液由1mol/L的氢氧化钠溶液、二甲基亚砜和环氧氯丙烷按体积比5:1:0.6组成。
实施例2
一种肿瘤康复型水产胶原蛋白肽食品,每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉12.4g,鲨鱼皮胶原蛋白肽粉8g,乳清蛋白粉3.5g,MCT脂肪10g,LCT脂肪11g,麦芽糊精11g,蔗糖10g,木糖20g,灵芝多糖2.4g,姬松茸多糖2.6g,烟酸4mg,叶酸41μg,生物素39μg,胆碱78.6mg,泛酸13mg,牛磺酸52mg, L-肉碱52mg,卵磷脂98mg,谷氨酰胺98mg,核苷酸9mg,精氨酸66mg,DHA 49mg,维生素A 1400IU,维生素D3 98IU,维生素E 21.1IU,维生素C 38mg,维生素B1 0.4mg,维生素B2 0.5mg,维生素B6 0.7mg,维生素K1 22.7μg,维生素B12 0.7μg,以及含有微量元素的多种无机盐。
其中所有所述无机盐中微量元素的含量如下:钙148mg,磷134mg,镁80mg,锌3.7mg,铁3.0mg,铜0.40mg,锰0.77mg,钠116.6mg,钾187.0mg,氯172.6mg,碘16.02μg,铬15.2μg,钼22.5μg,硒12μg。
其中,所述金枪鱼皮胶原蛋白肽粉中,分子量在600-1000Da区间内占比90%以上;所述鲨鱼皮胶原蛋白肽粉中,分子量在10000-12000Da以内占比90%以上。
所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉的制备方法如下:
a、原料解冻清洗:对鱼皮进行流水解冻,解冻时间为2h;完全解冻后将鱼皮洗净。
b、原料预处理:将鱼皮添加到5倍浓度为5wt%的氢氧化钠溶液中,在20℃下脱脂6h,然后取鱼皮用水洗净。
c、蒸煮熬胶:将鱼皮在90℃下进行蒸煮熬胶12h,取生成的鱼皮胶,并对鱼皮胶通过离心处理与油脂分离,离心速率为1000r/min。
d、酶解:将鱼皮胶添加到含有中性蛋白酶的酶解液中进行酶解;其中中性蛋白酶的浓度为0.05wt%,酶解液质量为鱼皮胶质量的4倍,酶解温度为30℃,酶解液pH至控制在6-8,酶解时间为60min。
e、炭脱、板框过滤:向酶解液中添加质量为酶解液1wt%的活性炭,并将酶解液加热到70℃,脱色50min;将脱色后的酶解液转移至板框过滤池内进行过滤,取澄清液。
f、分离纯化:将澄清液转移至泡沫分离柱中进行鼓气起泡,并收集泡沫液,,在鼓气的同时向泡沫分离柱中注水;鼓气速率为3L/min,注水速率为0.1L/min,泡沫分离柱中液体的装载高度与泡沫分离柱内径比为8:1,澄清液温度保持在25℃;待收集的泡沫液灭泡后,用离子交换器对泡沫液进行重金属分离;向重金属分离后的泡沫液中添加质量为泡沫液1%的磁性亲和微球并分散均匀,静置亲和吸附50min后利用磁场使磁性亲和微球聚集;分离出磁性亲和微球后,用pH值为7.2的Tris-HCl缓冲液对磁性亲和微球进行洗脱,再次利用磁场分离出磁性亲和微球后,得到洗脱液,将洗脱液在75℃下储存备用。
g、浓缩:将洗脱液先后输入双效浓缩锅和四效浓缩锅中进行浓缩,制得浓缩液,所述浓缩液的折光度控制在5,浓缩后浓缩液在50℃下储存。
h、膜过滤:将浓缩液通过二级0.22微米膜过滤器进行除杂除菌;其中膜过滤温度小于45℃,一级过滤压力小于0.25MPa,二级过滤压力小于0.4MPa。
i、多肽分级:采用超滤膜或纳滤膜对膜过滤后的浓缩液按分子量进行分离,得到目标分子量的胶原蛋白肽。将目标分子量的胶原蛋白肽稀释20倍,向稀释液中添加含钙无机盐,在40℃下螯合15min,接着向稀释液中添加含硒无机盐,在40℃下螯合15min;其中含钙无机盐、含硒无机盐的质量分别为稀释液质量的0.15%。
j、喷雾干燥:对胶原蛋白肽进行喷雾干燥,制得水产胶原蛋白肽粉;喷雾温度为80-90℃,喷雾干燥后水产胶原蛋白肽粉的含水率小于等于5wt%。
在金枪鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在1000Da以上的胶原蛋白肽,再用纳滤膜截留分子量在600Da以上的胶原蛋白肽,得到分子量在600-1000Da之间的胶原蛋白肽;在鲨鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在12000Da以上的胶原蛋白肽,再用超滤膜截留分子量在1000Da以上的胶原蛋白肽,得到分子量在10000-1200Da之间的胶原蛋白肽。
所述磁性亲和微球由以下方法制得:将海藻酸钠、聚乙二醇、壳聚糖、正庚烷、乙酸、水按质量比2:1:2:0.5:3:100混合溶解,搅拌均匀后制得混合液A;向混合液A中添加混合液A质量4%的四氧化三铁磁粉并分散均匀,得到混合液B;对混合液B进行超声波分散,同时向混合液B中匀速滴加混合液B质量40%的乳化液,乳化液在10min内滴加完毕,得到混合液C;先后向混合液C中添加混合液C质量0.1%的98wt%的戊二醛和混合液C质量0.5倍的3.5wt%的氯化钙溶液,充分搅拌,静置1h,生成磁性微球;利用磁场对液体中磁性微球进行聚集,取出磁性微球后进行清洗、干燥;将磁性微球浸泡在水中溶胀15min,然后取出磁性微球并添加到活化液中在35℃下活化80min,磁性微球与活化液的固液比为0.5g/mL;活化后取出磁性微球并洗净,将磁性微球与肝素按质量比1.5:1进行混合,得到悬浮液,将悬浮液pH值调节至4-5,然后向悬浮液中添加悬浮液体积1.5倍的3wt%的1-乙基-3-二甲氨丙基-碳二亚胺,在4℃下静置12h。生成磁性亲和微球,最后从悬浮液中取出磁性亲和微球,洗净、干燥,备用。
其中,所述乳化液为体积占比为30%的司盘-80无水乙醇混合液。所述活化液由1mol/L的氢氧化钠溶液、二甲基亚砜和环氧氯丙烷按体积比4:1:0.5组成。
实施例3
一种肿瘤康复型水产胶原蛋白肽食品,每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉14.4g,鲨鱼皮胶原蛋白肽粉7g,乳清蛋白粉4.5g,MCT脂肪12g,LCT脂肪9g,麦芽糊精14g,蔗糖14g,果糖14g,灵芝多糖2.6g,姬松茸多糖2.4g,烟酸4.1mg,叶酸43μg,生物素41μg,胆碱79mg,泛酸15mg,牛磺酸53mg, L-肉碱53mg,卵磷脂102mg,谷氨酰胺102mg,核苷酸11mg,精氨酸68mg,DHA 51mg,维生素A 1600IU,维生素D3 102IU,维生素E 21.5IU,维生素C 42mg,维生素B1 0.6mg,维生素B2 0.7mg,维生素B6 0.8mg,维生素K1 22.9μg,维生素B12 0.9μg,以及含有微量元素的多种无机盐。
其中所有所述无机盐中微量元素的含量如下:钙152mg,磷136mg,镁82mg,锌3.9mg,铁3.2mg,铜0.42mg,锰0.79mg,钠117.0mg,钾187.4mg,氯173.0mg,碘16.04μg,铬15.4μg,钼23.0μg,硒14μg。
其中,所述金枪鱼皮胶原蛋白肽粉中,分子量在600-1000Da区间内占比90%以上;所述鲨鱼皮胶原蛋白肽粉中,分子量在10000-12000Da以内占比90%以上。
所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉的制备方法如下:
a、原料解冻清洗:对鱼皮进行流水解冻,解冻时间为5h;完全解冻后将鱼皮洗净。
b、原料预处理:将鱼皮添加到10倍浓度为3wt%的氢氧化钠溶液中,在30℃下脱脂4h,然后取鱼皮用水洗净。
c、蒸煮熬胶:将鱼皮在100℃下进行蒸煮熬胶8h,取生成的鱼皮胶,并对鱼皮胶通过离心处理与油脂分离,离心速率为1000r/min。
d、酶解:将鱼皮胶添加到含有中性蛋白酶的酶解液中进行酶解;其中中性蛋白酶的浓度为0.25wt%,酶解液质量为鱼皮胶质量的倍,酶解温度为45℃,酶解液pH至控制在6-8,酶解时间为30min。
e、炭脱、板框过滤:向酶解液中添加质量为酶解液2wt%的活性炭,并将酶解液加热到80℃,脱色30min;将脱色后的酶解液转移至板框过滤池内进行过滤,取澄清液。
f、分离纯化:将澄清液转移至泡沫分离柱中进行鼓气起泡,并收集泡沫液,,在鼓气的同时向泡沫分离柱中注水;鼓气速率为5L/min,注水速率为0.3L/min,泡沫分离柱中液体的装载高度与泡沫分离柱内径比为10:1,澄清液温度保持在35℃;待收集的泡沫液灭泡后,用离子交换器对泡沫液进行重金属分离;向重金属分离后的泡沫液中添加质量为泡沫液2%的磁性亲和微球并分散均匀,静置亲和吸附70min后利用磁场使磁性亲和微球聚集;分离出磁性亲和微球后,用pH值为7.2的Tris-HCl缓冲液对磁性亲和微球进行洗脱,再次利用磁场分离出磁性亲和微球后,得到洗脱液,将洗脱液在85℃下储存备用。
g、浓缩:将洗脱液先后输入双效浓缩锅和四效浓缩锅中进行浓缩,制得浓缩液,所述浓缩液的折光度控制在6,浓缩后浓缩液在60℃下储存。
h、膜过滤:将浓缩液通过二级0.22微米膜过滤器进行除杂除菌;其中膜过滤温度小于45℃,一级过滤压力小于0.25MPa,二级过滤压力小于0.4MPa。
i、多肽分级:采用超滤膜或纳滤膜对膜过滤后的浓缩液按分子量进行分离,得到目标分子量的胶原蛋白肽。将目标分子量的胶原蛋白肽稀释30倍,向稀释液中添加含钙无机盐,在45℃下螯合10min,接着向稀释液中添加含硒无机盐,在45℃下螯合10min;其中含钙无机盐、含硒无机盐的质量分别为稀释液质量的0.2%。
j、喷雾干燥:对胶原蛋白肽进行喷雾干燥,制得水产胶原蛋白肽粉;喷雾温度为80-90℃,喷雾干燥后水产胶原蛋白肽粉的含水率小于等于5wt%。
在金枪鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在1000Da以上的胶原蛋白肽,再用纳滤膜截留分子量在600Da以上的胶原蛋白肽,得到分子量在600-1000Da之间的胶原蛋白肽;在鲨鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在12000Da以上的胶原蛋白肽,再用超滤膜截留分子量在1000Da以上的胶原蛋白肽,得到分子量在10000-1200Da之间的胶原蛋白肽。
所述磁性亲和微球由以下方法制得:将海藻酸钠、聚乙二醇、壳聚糖、正庚烷、乙酸、水按质量比3:1:2:0.5: 5:100混合溶解,搅拌均匀后制得混合液A;向混合液A中添加混合液A质量6%的四氧化三铁磁粉并分散均匀,得到混合液B;对混合液B进行超声波分散,同时向混合液B中匀速滴加混合液B质量60%的乳化液,乳化液在20min内滴加完毕,得到混合液C;先后向混合液C中添加混合液C质量0.2%的98wt%的戊二醛和混合液C质量1倍的2.5wt%的氯化钙溶液,充分搅拌,静置2h,生成磁性微球;利用磁场对液体中磁性微球进行聚集,取出磁性微球后进行清洗、干燥;将磁性微球浸泡在水中溶胀25min,然后取出磁性微球并添加到活化液中在45℃下活化40min,磁性微球与活化液的固液比为1.0g/mL;活化后取出磁性微球并洗净,将磁性微球与肝素按质量比2.5:1进行混合,得到悬浮液,将悬浮液pH值调节至4-5,然后向悬浮液中添加悬浮液体积2.5倍的3wt%的1-乙基-3-二甲氨丙基-碳二亚胺,在4℃下静置18h。生成磁性亲和微球,最后从悬浮液中取出磁性亲和微球,洗净、干燥,备用。
其中,所述乳化液为体积占比为40%的司盘-80无水乙醇混合液。所述活化液由1mol/L的氢氧化钠溶液、二甲基亚砜和环氧氯丙烷按体积比6:1:0.7组成。
本发明中所用原料、设备,若无特别说明,均为本领域的常用原料、设备;本发明中所用方法,若无特别说明,均为本领域的常规方法。
以上所述,仅是本发明的较佳实施例,并非对本发明作任何限制,凡是根据本发明技术实质对以上实施例所作的任何简单修改、变更以及等效变换,均仍属于本发明技术方案的保护范围。
Claims (10)
1.一种肿瘤康复型水产胶原蛋白肽食品,其特征在于每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉12.4-14.4g,鲨鱼皮胶原蛋白肽粉7-8g,乳清蛋白粉3.5-4.5g,MCT脂肪10-12g,LCT脂肪9-11g,碳水化合物41-42g,灵芝多糖2.4-2.6g,姬松茸多糖2.4-2.6g,烟酸4-4.1mg,叶酸41-43μg,生物素39-41μg,胆碱78.6-79mg,泛酸13-15mg,牛磺酸52-53mg, L-肉碱52-53mg,卵磷脂98-102mg,谷氨酰胺98-102mg,核苷酸9-11mg,精氨酸66-68mg,DHA 49-51mg,维生素A 1400-1600IU,维生素D3 98-102IU,维生素E 21.1-21.5IU,维生素C 38-42mg,维生素B1 0.4-0.6mg,维生素B2 0.5-0.7mg,维生素B6 0.7-0.8mg,维生素K1 22.7-22.9μg,维生素B12 0.7-0.9μg,以及含有微量元素的多种无机盐;
其中所有所述无机盐中微量元素的含量如下:钙148-152mg,磷134-136mg,镁80-82mg,锌3.7-3.9mg,铁3.0-3.2mg,铜0.40-0.42mg,锰0.77-0.79mg,钠116.6-117.0mg,钾187.0-187.4mg,氯172.6-173.0mg,碘16.02-16.04μg,铬15.2-15.4μg,钼22.5-23.0μg,硒12-14μg。
2.如权利要求1所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,每100g中包含以下物质:
金枪鱼皮胶原蛋白肽粉13.4g,鲨鱼皮胶原蛋白肽粉7.5g,乳清蛋白粉4g,MCT脂肪11g,LCT脂肪10g,碳水化合物41.6g,灵芝多糖2.5g,姬松茸多糖2.5g,烟酸4.05g,叶酸42μg,生物素40μg,胆碱78.8mg,泛酸14mg,牛磺酸52.5mg, L-肉碱52.5mg,卵磷脂100mg,谷氨酰胺100mg,核苷酸10mg,精氨酸67mg,DHA 50mg,维生素A 1500IU,维生素D3 100IU,维生素E 21.3IU,维生素C 40mg,维生素B1 0.5mg,维生素B2 0.6mg,维生素B6 0.75mg,维生素K1 22.8μg,维生素B12 0.8μg,以及含有微量元素的多种无机盐;
其中所有所述无机盐中微量元素的含量如下:钙150mg,磷135mg,镁81mg,锌3.8mg,铁3.1mg,铜0.41mg,锰0.78mg,钠116.8mg,钾187.2mg,氯172.8mg,碘16.03μg,铬15.3μg,钼22.75μg,硒13μg。
3.如权利要求1或2所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述金枪鱼皮胶原蛋白肽粉中,分子量在600-1000Da区间内占比90%以上;所述鲨鱼皮胶原蛋白肽粉中,分子量在10000-12000Da以内占比90%以上。
4.如权利要求1所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述碳水化合物选自聚葡糖糖、麦芽糊精、蔗糖、果糖、木糖中的至少两种。
5.如权利要求1所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉的制备方法如下:
a、原料解冻清洗:对鱼皮进行流水解冻,解冻时间为2-5h;完全解冻后将鱼皮洗净;
b、原料预处理:将鱼皮添加到5-10倍浓度为3-5wt%的氢氧化钠溶液中,在20-30℃下脱脂4-6h,然后取鱼皮用水洗净;
c、蒸煮熬胶:将鱼皮在90-100℃下进行蒸煮熬胶8-12h,取生成的鱼皮胶,并对鱼皮胶通过离心处理与油脂分离,离心速率为1000r/min;
d、酶解:将鱼皮胶添加到含有中性蛋白酶的酶解液中进行酶解;其中中性蛋白酶的浓度为0.05-0.25wt%,酶解液质量为鱼皮胶质量的2-4倍,酶解温度为30-45℃,酶解液pH至控制在6-8,酶解时间为30-60min;
e、炭脱、板框过滤:向酶解液中添加质量为酶解液1-2wt%的活性炭,并将酶解液加热到70-80℃,脱色30-50min;将脱色后的酶解液转移至板框过滤池内进行过滤,取澄清液;
f、分离纯化:将澄清液转移至泡沫分离柱中进行鼓气起泡,并收集泡沫液,,在鼓气的同时向泡沫分离柱中注水;鼓气速率为3-5L/min,注水速率为0.1-0.3L/min,泡沫分离柱中液体的装载高度与泡沫分离柱内径比为8-10:1,澄清液温度保持在25-35℃;待收集的泡沫液灭泡后,用离子交换器对泡沫液进行重金属分离;向重金属分离后的泡沫液中添加质量为泡沫液1-2%的磁性亲和微球并分散均匀,静置亲和吸附50-70min后利用磁场使磁性亲和微球聚集;分离出磁性亲和微球后,用pH值为7.2的Tris-HCl缓冲液对磁性亲和微球进行洗脱,再次利用磁场分离出磁性亲和微球后,得到洗脱液,将洗脱液在75-85℃下储存备用;
g、浓缩:将洗脱液先后输入双效浓缩锅和四效浓缩锅中进行浓缩,制得浓缩液,所述浓缩液的折光度控制在5-6,浓缩后浓缩液在50-60℃下储存;
h、膜过滤:将浓缩液通过二级0.22微米膜过滤器进行除杂除菌;其中膜过滤温度小于45℃,一级过滤压力小于0.25MPa,二级过滤压力小于0.4MPa;
i、多肽分级:采用超滤膜或纳滤膜对膜过滤后的浓缩液按分子量进行分离,得到目标分子量的胶原蛋白肽;
j、喷雾干燥:对胶原蛋白肽进行喷雾干燥,制得胶原蛋白肽粉;喷雾温度为80-90℃,喷雾干燥后水产胶原蛋白肽粉的含水率小于等于5wt%。
6.如权利要求5所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,在金枪鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在1000Da以上的胶原蛋白肽,再用纳滤膜截留分子量在600Da以上的胶原蛋白肽,得到分子量在600-1000Da之间的胶原蛋白肽;在鲨鱼皮胶原蛋白肽粉的制备过程中,在进行多肽分级时,先用超滤膜截留分子量在12000Da以上的胶原蛋白肽,再用超滤膜截留分子量在1000Da以上的胶原蛋白肽,得到分子量在10000-1200Da之间的胶原蛋白肽。
7.如权利要求5所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述磁性亲和微球由以下方法制得:将海藻酸钠、聚乙二醇、壳聚糖、正庚烷、乙酸、水按质量比2-3:1:2:0.5:3-5:100混合溶解,搅拌均匀后制得混合液A;向混合液A中添加混合液A质量4-6%的四氧化三铁磁粉并分散均匀,得到混合液B;对混合液B进行超声波分散,同时向混合液B中匀速滴加混合液B质量40-60%的乳化液,得到混合液C;先后向混合液C中添加混合液C质量0.1-0.2%的98wt%的戊二醛和混合液C质量0.5-1倍的2.5-3.5wt%的氯化钙溶液,充分搅拌,静置1-2h,生成磁性微球;利用磁场对液体中磁性微球进行聚集,取出磁性微球后进行清洗、干燥;将磁性微球浸泡在水中溶胀15-25min,然后取出磁性微球并添加到活化液中在35-45℃下活化40-80min,磁性微球与活化液的固液比为0.5-1.0g/mL;活化后取出磁性微球并洗净,将磁性微球与肝素按质量比1.5-2.5:1进行混合,得到悬浮液,将悬浮液pH值调节至4-5,然后向悬浮液中添加悬浮液体积1.5-2.5倍的3wt%的1-乙基-3-二甲氨丙基-碳二亚胺,在4℃下静置12-18h;生成磁性亲和微球,最后从悬浮液中取出磁性亲和微球,洗净、干燥,备用。
8.如权利要求7所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述
乳化液为体积占比为30-40%的司盘-80无水乙醇混合液,乳化液在10-20min内滴加完毕。
9.如权利要求7所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述活化液由1mol/L的氢氧化钠溶液、二甲基亚砜和环氧氯丙烷按体积比4-6:1:0.5-0.7组成。
10.如权利要求5所述的一种肿瘤康复型水产胶原蛋白肽食品,其特征在于,所述金枪鱼皮胶原蛋白肽粉和所述鲨鱼皮胶原蛋白肽粉在制备过程中,在多肽分级之后、喷雾干燥之前,将目标分子量的胶原蛋白肽稀释10-30倍,向稀释液中添加含钙无机盐,在35-45℃下螯合10-20min,接着向稀释液中添加含硒无机盐,在35-45℃下螯合10-20min;其中含钙无机盐、含硒无机盐的质量分别为稀释液质量的0.1-0.2%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610314066.7A CN105982336A (zh) | 2016-05-13 | 2016-05-13 | 一种肿瘤康复型水产胶原蛋白肽食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610314066.7A CN105982336A (zh) | 2016-05-13 | 2016-05-13 | 一种肿瘤康复型水产胶原蛋白肽食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105982336A true CN105982336A (zh) | 2016-10-05 |
Family
ID=57044714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610314066.7A Pending CN105982336A (zh) | 2016-05-13 | 2016-05-13 | 一种肿瘤康复型水产胶原蛋白肽食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105982336A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107981339A (zh) * | 2017-12-07 | 2018-05-04 | 湖南共为特殊医学配方食品有限公司 | 肿瘤全营养配方食品 |
CN108541804A (zh) * | 2018-03-20 | 2018-09-18 | 武汉科泰生化科技股份有限公司 | 一种利用小麦水解蛋白制备肠膜营养肽微球的方法 |
CN109078164A (zh) * | 2018-08-22 | 2018-12-25 | 厦门肽王基因科技有限公司 | 灰星鲨鱼皮混合型蛋白肽作为骨骼发育促进剂和微量元素补充剂的应用 |
CN114029085A (zh) * | 2021-12-06 | 2022-02-11 | 中触媒新材料股份有限公司 | 一种烯烃环氧化催化剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101816431A (zh) * | 2010-04-30 | 2010-09-01 | 浙江省医学科学院 | 具有改善骨质疏松、增加骨密度功能的珍肽強骨胶囊或片剂及其制备方法 |
CN103169953A (zh) * | 2013-03-20 | 2013-06-26 | 天津大学 | 一种胶原蛋白肽-阿胶口服液及制备方法 |
CN103285791A (zh) * | 2013-05-10 | 2013-09-11 | 深圳大学 | 一种基于金属离子改性的磁性介孔二氧化硅核壳结构亲和微球及其制备方法和应用 |
-
2016
- 2016-05-13 CN CN201610314066.7A patent/CN105982336A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101816431A (zh) * | 2010-04-30 | 2010-09-01 | 浙江省医学科学院 | 具有改善骨质疏松、增加骨密度功能的珍肽強骨胶囊或片剂及其制备方法 |
CN103169953A (zh) * | 2013-03-20 | 2013-06-26 | 天津大学 | 一种胶原蛋白肽-阿胶口服液及制备方法 |
CN103285791A (zh) * | 2013-05-10 | 2013-09-11 | 深圳大学 | 一种基于金属离子改性的磁性介孔二氧化硅核壳结构亲和微球及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
唐传核等: "植物***研究概况(Ⅱ)――生理功能进展", 《中国食品添加剂》 * |
陈华等: "海洋胶原蛋白肽的制备及生物活性研究进展", 《中国食物与营养》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107981339A (zh) * | 2017-12-07 | 2018-05-04 | 湖南共为特殊医学配方食品有限公司 | 肿瘤全营养配方食品 |
CN108541804A (zh) * | 2018-03-20 | 2018-09-18 | 武汉科泰生化科技股份有限公司 | 一种利用小麦水解蛋白制备肠膜营养肽微球的方法 |
CN109078164A (zh) * | 2018-08-22 | 2018-12-25 | 厦门肽王基因科技有限公司 | 灰星鲨鱼皮混合型蛋白肽作为骨骼发育促进剂和微量元素补充剂的应用 |
CN109078164B (zh) * | 2018-08-22 | 2022-04-01 | 厦门肽王基因科技有限公司 | 灰星鲨鱼皮混合型蛋白肽作为骨骼发育促进剂和微量元素补充剂的应用 |
CN114029085A (zh) * | 2021-12-06 | 2022-02-11 | 中触媒新材料股份有限公司 | 一种烯烃环氧化催化剂及其制备方法和应用 |
CN114029085B (zh) * | 2021-12-06 | 2024-02-27 | 中触媒新材料股份有限公司 | 一种烯烃环氧化催化剂及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105982337A (zh) | 一种用于骨质疏松和关节炎辅助治疗的水产胶原蛋白肽食品 | |
CN105982331A (zh) | 一种创伤修复通用型水产胶原蛋白肽食品 | |
CN109452521B (zh) | 一种辅助降尿酸肽固体饮料、制备方法及用途 | |
CN105982336A (zh) | 一种肿瘤康复型水产胶原蛋白肽食品 | |
CN101530196B (zh) | 一种供术后患者食用含短肽的特殊膳食用食品配方 | |
CN112089051A (zh) | 用于改善肿瘤患者身体炎性体征的营养组合物及制备方法 | |
CN102524872B (zh) | 一种参肽氨基酸饮料 | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
CN1692782A (zh) | 降压好酸奶片 | |
CN106689947A (zh) | 含大豆肽的电解质运动饮料 | |
CN105519961B (zh) | 一种用于透析患者的肠内营养制剂及其制备方法 | |
CN107495387A (zh) | 一种作为运动补剂的海洋多肽特膳食品 | |
CN104855975A (zh) | 肌肉衰减综合征非全营养配方食品 | |
CN113615783A (zh) | 一种牦牛胶原蛋白肽运动饮料 | |
CN103783619A (zh) | 一种运动饮料及其制备方法 | |
CN114343172A (zh) | 中药组合物在改善慢性肝病患者肝功能的食品中的应用、营养粉及制备方法 | |
CN114214366A (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
CN1597703A (zh) | 低分子海藻酸钾及其应用 | |
CN111387486A (zh) | 用于肝病患者的特殊医学用途配方营养粉及其制备方法 | |
CN105639642A (zh) | 一种适用于产后及人流术后康复营养食品 | |
CN105166901A (zh) | 一种透析患者用营养组合物 | |
CN108175006A (zh) | 一种黑木耳多糖饮料及其制备方法 | |
CN113068784A (zh) | 一种缓解身体疼痛的sod饮液及其制备方法 | |
CN113287703A (zh) | 一种舞茸绣球菌多糖小肽固体饮料及其生产方法 | |
CN112244191A (zh) | 一种双参肽功能性固体饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161005 |